Iovance Biotherapeutics (IOVA) Soars 23% on Bullish Outlook

On July 23, 2025, Iovance Biotherapeutics (IOVA) saw a significant 23% rise in pre-market trading, reflecting a surge in investor interest and optimism surrounding the company's future prospects.

Analysts have been closely monitoring Iovance, with several recent changes in their recommendations and price targets. Chardan Capital, for instance, has maintained a "buy" rating on the stock but reduced its price target from $30 to $25. This adjustment comes after a series of downgrades from other analysts, including Goldman Sachs, UBS, and Truist, who have revised their ratings from "buy" to "sell" or "neutral" due to concerns over the company's performance and guidance.

Despite these mixed signals, some analysts remain bullish on Iovance. Geulah Livshits from Chardan Capital recently set a price target of $25 for IOVA, indicating confidence in the company's long-term potential. The technical and fundamental set-up, including a 34.5% short interest, suggests that the current rise could be just the beginning of a year-long short squeeze.

Additionally, Iovance recently appointed Corleen Roche as its new Chief Financial Officer, effective August 6, 2025. This strategic move is expected to strengthen the company's financial management and operational efficiency, further bolstering investor confidence.